These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. De Stefano V; Qi X; Betti S; Rossi E Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846 [TBL] [Abstract][Full Text] [Related]
6. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms. Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552 [TBL] [Abstract][Full Text] [Related]
7. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients. Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis. Li M; De Stefano V; Song T; Zhou X; Guo Z; Zhu J; Qi X Thromb Res; 2018 Jul; 167():96-103. PubMed ID: 29803161 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189 [TBL] [Abstract][Full Text] [Related]
10. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. Turon F; Cervantes F; Colomer D; Baiges A; Hernández-Gea V; Garcia-Pagán JC J Hepatol; 2015 Jan; 62(1):72-4. PubMed ID: 25173966 [TBL] [Abstract][Full Text] [Related]
11. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR. Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326 [TBL] [Abstract][Full Text] [Related]
12. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474 [TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
15. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Tang Q; Zhang XW; Xia L; Jiang NK Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393 [TBL] [Abstract][Full Text] [Related]
16. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics. Lang T; Nie Y; Wang Z; Huang Q; An L; Wang Y; Wufuer G; Maimaiti A; Fu L; Li Y; Zhang X; Aisimutula A; Wang X; Zhu L; Liu H; Mao M J Int Med Res; 2018 Nov; 46(11):4650-4659. PubMed ID: 30084272 [TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380 [TBL] [Abstract][Full Text] [Related]